- #ASCO26: Summit, Akeso drug reduces death by 34% in China lung cancer studyCHICAGO — The leading drug in biopharma's hottest immunotherapy race reduced the risk of death by 34% in previously untreated Chinese lung cancer patients, compared to standard immunotherapy plus c…Endpoints · 1mo ago↗ source
- Akeso, Summit drug extends survival in closely watched lung cancer trialThough ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study, the total survival benefit of four months stirred debate and pressured company shares.BioPharma Dive · 1mo ago↗ source
- ‘Unprecedented’ Revolution data point to paradigm shift in pancreatic cancerHighly anticipated data presented at ASCO confirmed what’s been heralded as a medical breakthrough against a historically tough-to-treat tumor.